The SB221 trial was structured to evaluate the combination’s tolerability, pharmacodynamics, safety and pharmacokinetics.

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

PROCEPT BioRobotics announced positive WATER III trial results for Aquablation therapy in large prostates, showing effective outcomes and reduced complications. PROCEPT BioRobotics Corporation ...